Stock Events

Stock Events

Galecto Inc 

$29.97
36
-$3.02-9.15% Wednesday 17:51

Statistics

Day High
29.99
Day Low
29.94
52W High
34.14
52W Low
2.58
Volume
16,693
Avg. Volume
-
Mkt Cap
1.84B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

5AugExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Next
-5.13
-3.55
-1.97
-0.39
Expected EPS
-0.413502
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-209.84MNet Income

Analyst Ratings

43.71Average Price Target
The highest estimate is 50.00.
From 7 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Madrigal Pharmaceuticals
MDGL
Mkt Cap12.37B
Madrigal Pharmaceuticals is involved in developing therapies for fibrosis, particularly NASH, a direct area of competition with Galecto.
ProQR Therapeutics N.V
PRQR
Mkt Cap244.14M
ProQR Therapeutics works on treatments for fibrosis among other diseases, positioning it as a competitor in the fibrosis space.
Gilead Sciences
GILD
Mkt Cap161.19B
Gilead Sciences has a strong portfolio in treating fibrotic diseases, making it a major competitor to Galecto.
Vertex Pharmaceuticals
VRTX
Mkt Cap123.19B
Vertex Pharmaceuticals has expanded its focus to include fibrosis, directly competing with Galecto's pipeline.
Pfizer
PFE
Mkt Cap137.76B
Pfizer has a broad range of treatments including for fibrosis, positioning it as a competitor across multiple areas including those targeted by Galecto.
Abbvie
ABBV
Mkt Cap438.31B
AbbVie has research interests in fibrosis, making it a competitor in the therapeutic area Galecto is targeting.
Novartis
NVS
Mkt Cap293.94B
Novartis has a diversified portfolio that includes treatments for fibrosis, competing with Galecto in the fibrosis therapeutic area.

About

Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company’s lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients. It also develops GB3226, a small molecule inhibitor of ENL-YEATS and FLT3 for the treatment of acute myeloid leukemia. Damora Therapeutics, Inc. was founded in 2011 and is headquartered in Waltham, Massachusetts.
Show more...
CEO
Ms. Lori C. Firmani
Employees
7
Country
United States
ISIN
US36322Q1076

Listings

BOATS
BOATS
GLTO.BOATS
XNAS
US
DMRA

0 Comments

Share your thoughts

FAQ

What is Galecto Inc stock price today?▼
The current price of GLTO is $29.97 USD — it has decreased by -9.15% in the past 24 hours. Watch Galecto Inc stock price performance more closely on the chart.
What is Galecto Inc stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Galecto Inc stocks are traded under the ticker GLTO.
Is Galecto Inc stock price growing?▼
GLTO stock has risen by +0% compared to the previous week, the month change is a -2.54% fall, over the last year Galecto Inc has showed a +786.69% increase.
What is Galecto Inc market cap?▼
Today Galecto Inc has the market capitalization of 1.84B
What is Galecto Inc revenue for the last year?▼
Galecto Inc revenue for the last year amounts to 0 USD.
What is Galecto Inc net income for the last year?▼
GLTO net income for the last year is -209.84M USD.
How many employees does Galecto Inc have?▼
As of August 09, 2026, the company has 7 employees.
In which sector is Galecto Inc located?▼
Galecto Inc operates in the Health & Wellness sector.
When did Galecto Inc complete a stock split?▼
The last stock split for Galecto Inc was on August 30, 2024 with a ratio of 1:25.
Where is Galecto Inc headquartered?▼
Galecto Inc is headquartered in Copenhagen, United States.